Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitors

Radiology and Oncology

Lopes Gilberto¹  Rossi Antonio²  Di Maio Massimo³  Perme Maja Pohar⁴  Zwitter Matjaz⁵ 

[1] Centro Paulista de Oncologia e HCor Onco, members of the Oncoclinicas do Brasil Group, Sao Paulo, Brazil and Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA;Division of Medical Oncology, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo (FG), Italy;Division of Medical Oncology, Mauriziano Hospital, Oncology Department, University of Turin, Torino, Italy;Institute for Biostatistics and Medical Informatics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia;Institute of Oncology Ljubljana, Ljubljana, Slovenia;

关键词: nsclc;    intercalated treatment;    egfr;    tyrosine-kinase inhibitors;   

DOI  :  10.1515/raon-2017-0029

来源: DOAJ

【 摘 要 】

When treating patients with advanced non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors and chemotherapy, intercalated schedule with time separation between the two classes of drugs should avoid their mutual antagonism. In a survey of published trials, we focus on relation between eligibility criteria and effectiveness of intercalated treatment.

【 授权许可】

Unknown